Darzalex SC - Guia Prático

DARZALEX^® SC practical guidance

DARZALEX^® SC dosing and treatment schedules

Single-use vial, fixed dose of 1800 mg DARZALEX^® and 30000 units of recombinant human hyaluronidase PH20 (ENHANZE^® drug delivery technology)^[1]^[2]
- Fixed dose reduces wastage, risk of miscalculating dose and preparation time
Administration from the first dose of DARZALEX^® SC treatment, and from the next scheduled dose in patients who are currently on DARZALEX^® IV^[1]
Vials do not require filtration or IV pump^[1]
DARZALEX^® solution for injection is a colourless-to-yellow liquid^[1]
Treatment schedules with DARZALEX^® SC remain the same, and DARZALEX^® SC is available in all approved DARZALEX^® IV indications^[1]

Quick downloads

SC Checklist beginning of treatment

Includes a first use checklist of Darzalex^® SC.

Darzalex^® SC Practical Guide

Includes DARZALEX^® SC handling and administration info, pre and post-injection medications, and more

Glossary

AE: adverse event

IV: intravenous

MOA: mode of action

rHuPH20: recombinant human hyaluronidase

PH20 SC: subcutaneous

Para visualizar o IECRCM de Darzalex, veja aqui.

Referências

[1]

RCM DARZALEX ^®. Acedido em março de 2022. Disponível em www.ema.europa.eu

[2]

Chari A et al. Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study. Oral presentation at the 59th American Society of Hematology annual meeting; December 9–12, 2017; Atlanta, GA; Abstract 838.

CP-287862 - March 2022

DARZALEX® SC practical guidance

DARZALEX® SC dosing and treatment schedules